Biogen nabs speedy FDA review for controversial Alzheimer’s drug

Biogen nabs speedy FDA review for controversial Alzheimer’s drug

Source: 
Fierce Biotech
snippet: 


Biogen’s aducanumab is inching closer to an FDA decision. The Big Biotech, along with partner Eisai, announced on Friday that the FDA accepted its regulatory submission for aducanumab, its once-failed Alzheimer’s drug—with priority review to boot.